The review provides an overview of the approaches, applications, and methods for ester prodrugs. Ester prodrugs are pharmacologically inactive compounds in their original form but become active drugs on biotransformation within the body, which offers advantages concerning the solubility, stability, and targeted delivery of the active drug. Several approaches of ester prodrugs have been reviewed in this review, including simple ester prodrugs, amino acid ester prodrugs, sugar ester prodrugs, lipid ester prodrugs, and polymeric ester prodrugs. This review incorporates in vitro and in vivo methods as well as the characterization of physical and chemical properties for ester prodrugs, cell culture systems, enzymatic assays, and animal models—all of these having a very important bearing on the evaluation of stability, bioavailability, and efficacy for ester prodrugs. While the benefits of using ester prodrugs are significant, there are also disadvantages like instability, poor or variable enzymatic hydrolysis, and toxicity from released promoieties or by-products. This review discusses solutions to the various limitations that include enhancing stability with ionizable promoieties and using physiologically-based pharmacokinetic modeling. The review also highlights the application of ester prodrugs in neurological disorders, such as Parkinson’s disease, and the ongoing efforts to address the critical limitations in treatment efficacy. Future prodrug strategies are poised to advance significantly by harnessing diverse transport mechanisms across the blood-brain barrier and integrating nanotechnology.
Choudhary, D., Goykar, H., Kalyane, D., Sreeharsha, N. and Tekade, R.K. (2020) Prodrug Design for Improving the Biopharmaceutical Properties of Therapeutic Drugs. In: Tekade, R.K., Ed., The Future of Pharmaceutical Product Development and Research , Elsevier, 179-226. https://doi.org/10.1016/b978-0-12-814455-8.00006-2
Dubey, S. and Valecha, V. (2014) Prodrugs: A Review. World Journal of Pharmaceutical Research , 3, 277-297.
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., et al . (2008) Prodrugs: Design and Clinical Applications. Nature Reviews Drug Discovery , 7, 255-270. https://doi.org/10.1038/nrd2468
Zawilska, J.B., Wojcieszak, J. and Olejniczak, A.B. (2013) Prodrugs: A Challenge for the Drug Development. Pharmacological Reports , 65, 1-14. https://doi.org/10.1016/s1734-1140(13)70959-9
Testa, B. (2004) Prodrug Research: Futile or Fertile? Biochemical Pharmacology , 68, 2097-2106. https://doi.org/10.1016/j.bcp.2004.07.005
Hajnal, K., Gabriel, H., Aura, R., Erzsébet, V. and Blanka, S.S. (2016) Prodrug Strategy in Drug Development. Acta Medica Marisiensis , 62, 356-362. https://doi.org/10.1515/amma-2016-0032
Perez, C., Daniel, K.B. and Cohen, S.M. (2013) Evaluating Prodrug Strategies for Esterase‐triggered Release of Alcohols. ChemMedChem , 8, 1662-1667. https://doi.org/10.1002/cmdc.201300255
Hamada, Y. (2017) Recent Progress in Prodrug Design Strategies Based on Generally Applicable Modifications. Bioorganic & Medicinal Chemistry Letters , 27, 1627-1632. https://doi.org/10.1016/j.bmcl.2017.02.075
Wang, Z., Cheng, L.P., Zhang, X.H., Pang, W., Li, L. and Zhao, J.L. (2017) Design, Synthesis and Biological Evaluation of Novel Oseltamivir Derivatives as Potent Neuraminidase Inhibitors. Bioorganic & Medicinal Chemistry Letters , 27, 5429-5435. https://doi.org/10.1016/j.bmcl.2017.11.003
Vig, B.S., Huttunen, K.M., Laine, K. and Rautio, J. (2013) Amino Acids as Promoieties in Prodrug Design and Development. Advanced Drug Delivery Reviews , 65, 1370-1385. https://doi.org/10.1016/j.addr.2012.10.001
Huttunen, K.M. (2024) Improving Drug Delivery to the Brain: The Prodrug Approach. Expert Opinion on Drug Delivery , 21, 683-693. https://doi.org/10.1080/17425247.2024.2355180
Huttunen, K.M. (2018) Identification of Human, Rat and Mouse Hydrolyzing Enzymes Bioconverting Amino Acid Ester Prodrug of Ketoprofen. Bioorganic Chemistry , 81, 494-503. https://doi.org/10.1016/j.bioorg.2018.09.018
Esterase-Responsive Nanoparticles
Hydrolysis
Cancer Treatment
Cardiovascular Diseases
Neurological Disorders
Thompson, B.R., Shi, J., Zhu, H. and Smith, D.E. (2020) Pharmacokinetics of Gemcitabine and Its Amino Acid Ester Prodrug Following Intravenous and Oral Administrations in Mice. Biochemical Pharmacology , 180, Article ID: 114127. https://doi.org/10.1016/j.bcp.2020.114127
Haddad, F., Sawalha, M., Khawaja, Y., Najjar, A. and Karaman, R. (2017) Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease. Molecules , 23, Article 40. https://doi.org/10.3390/molecules23010040
Shimoda, K., Hamada, H. and Hamada, H. (2008) Chemo-Enzymatic Synthesis of Ester-Linked Taxol-Oligosaccharide Conjugates as Potential Prodrugs. Tetrahedron Letters , 49, 601-604. https://doi.org/10.1016/j.tetlet.2007.11.156
Zheng, Y., Zheng, M., Ma, Z., Xin, B., Guo, R. and Xu, X. (2015) Sugar Fatty Acid Esters. In: Ahmad, M.U. and Xu, X.B., Eds., Polar Lipids , Elsevier, 215-243. https://doi.org/10.1016/b978-1-63067-044-3.50012-1
Zaro, J.L. (2014) Lipid-Based Drug Carriers for Prodrugs to Enhance Drug Delivery. The AAPS Journal , 17, 83-92. https://doi.org/10.1208/s12248-014-9670-z
Mura, S., Bui, D.T., Couvreur, P. and Nicolas, J. (2015) Lipid Prodrug Nanocarriers in Cancer Therapy. Journal of Controlled Release , 208, 25-41. https://doi.org/10.1016/j.jconrel.2015.01.021
Khandare, J. and Minko, T. (2006) Polymer-Drug Conjugates: Progress in Polymeric Prodrugs. Progress in Polymer Science , 31, 359-397. https://doi.org/10.1016/j.progpolymsci.2005.09.004
Li, Y., Ye, C., Cai, C., Zhao, M., Han, N., Liu, Z., et al . (2020) Design and Synthesis of Polymer Prodrugs for Improving Water-Solubility, Pharmacokinetic Behavior and Antitumor Efficacy of Txa9. Pharmaceutical Research , 37, Article No. 66. https://doi.org/10.1007/s11095-020-02789-w
Rautio, J., Meanwell, N.A., Di, L. and Hageman, M.J. (2018) The Expanding Role of Prodrugs in Contemporary Drug Design and Development. Nature Reviews Drug Discovery , 17, 559-587. https://doi.org/10.1038/nrd.2018.46
Lesniewska-Kowiel, M.A. and Muszalska, I. (2017) Strategies in the Designing of Prodrugs, Taking into Account the Antiviral and Anticancer Compounds. European Journal of Medicinal Chemistry , 129, 53-71. https://doi.org/10.1016/j.ejmech.2017.02.011
Miao, H., Chen, X. and Luan, Y. (2020) Small Molecular Gemcitabine Prodrugs for Cancer Therapy. Current Medicinal Chemistry , 27, 5562-5582. https://doi.org/10.2174/0929867326666190816230650
Dong, H., Pang, L., Cong, H., Shen, Y. and Yu, B. (2019) Application and Design of Esterase-Responsive Nanoparticles for Cancer Therapy. Drug Delivery , 26, 416-432. https://doi.org/10.1080/10717544.2019.1588424
Chen, W., Zhong, Y., Feng, N., Guo, Z., Wang, S. and Xing, D. (2021) New Horizons in the Roles and Associations of COX-2 and Novel Natural Inhibitors in Cardiovascular Diseases. Molecular Medicine , 27, Article No. 123. https://doi.org/10.1186/s10020-021-00358-4
Polhemus, D.J., Li, Z., Pattillo, C.B., Gojon, G., Gojon, G., Giordano, T., et al . (2015) A Novel Hydrogen Sulfide Prodrug, sg1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients. Cardiovascular Therapeutics , 33, 216-226. https://doi.org/10.1111/1755-5922.12128
Xia, X., Zhou, Y. and Gao, H. (2021) Prodrug Strategy for Enhanced Therapy of Central Nervous System Disease. Chemical Communications , 57, 8842-8855. https://doi.org/10.1039/d1cc02940a
He, X., Sugawara, M., Takekuma, Y. and Miyazaki, K. (2004) Absorption of Ester Prodrugs in Caco-2 and Rat Intestine Models. Antimicrobial Agents and Chemotherapy , 48, 2604-2609. https://doi.org/10.1128/aac.48.7.2604-2609.2004
Hong, X., Cai, Z., Zhou, F., Jin, X., Wang, G., Ouyang, B., et al . (2022) Improved Pharmacokinetics of Tenofovir Ester Prodrugs Strengthened the Inhibition of HBV Replication and the Rebalance of Hepatocellular Metabolism in Preclinical Models. Frontiers in Pharmacology , 13, Article 9329374. https://doi.org/10.3389/fphar.2022.932934
Hosokawa, M. (2008) Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs. Molecules , 13, 412-431. https://doi.org/10.3390/molecules13020412
Sun, H. (2012) Capture Hydrolysis Signals in the Microsomal Stability Assay: Molecular Mechanisms of the Alkyl Ester Drug and Prodrug Metabolism. Bioorganic & Medicinal Chemistry Letters , 22, 989-995. https://doi.org/10.1016/j.bmcl.2011.12.005
Ratnatilaka Na Bhuket, P., Jithavech, P., Ongpipattanakul, B. and Rojsitthisak, P. (2019) Interspecies Differences in Stability Kinetics and Plasma Esterases Involved in Hydrolytic Activation of Curcumin Diethyl Disuccinate, a Prodrug of Curcumin. RSC Advances , 9, 4626-4634. https://doi.org/10.1039/c8ra08594c
Vandamme, T. (2014) Use of Rodents as Models of Human Diseases. Journal of Pharmacy and Bioallied Sciences , 6, 2-9. https://doi.org/10.4103/0975-7406.124301
Padilla, A.M., Wang, W., Akama, T., Carter, D.S., Easom, E., Freund, Y., et al . (2022) Discovery of an Orally Active Benzoxaborole Prodrug Effective in the Treatment of Chagas Disease in Non-Human Primates. Nature Microbiology , 7, 1536-1546. https://doi.org/10.1038/s41564-022-01211-y
Chen, L., Zhou, L., Huang, J., Wang, Y., Yang, G., Tan, Z., et al . (2018) Single-and Multiple-Dose Trials to Determine the Pharmacokinetics, Safety, Tolerability, and Sex Effect of Oral Ginsenoside Compound K in Healthy Chinese Volunteers. Frontiers in Pharmacology , 8, Article 965. https://doi.org/10.3389/fphar.2017.00965
Cavallaro, G., Licciardi, M., Caliceti, P., Salmaso, S. and Giammona, G. (2004) Synthesis, Physico-Chemical and Biological Characterization of a Paclitaxel Macromolecular Prodrug. European Journal of Pharmaceutics and Biopharmaceutics , 58, 151-159. https://doi.org/10.1016/j.ejpb.2004.02.012